Department of Medicine, Lincoln Medical Center, Bronx, NY, USA.
Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, USA.
J Hematol Oncol. 2020 Sep 17;13(1):125. doi: 10.1186/s13045-020-00962-7.
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.
B 细胞成熟抗原 (BCMA) 是多发性骨髓瘤 (MM) 的一种新型治疗靶点，因为它在恶性浆细胞 (PC) 中高度选择性表达。多种 BCMA 靶向治疗药物，包括抗体药物偶联物 (ADC)、嵌合抗原受体 (CAR)-T 细胞和双特异性 T 细胞衔接器 (BiTE)，在复发和难治性 MM 患者中取得了显著的临床反应。BCMA 靶向 ADC belantamab mafodotin-blmf (GSK2857916) 刚刚被批准用于高度难治性 MM。本文总结了 BCMA 的分子和生理特性以及不同临床开发阶段的 BCMA 靶向免疫治疗药物。
